Moving forward, the availability and use of ERBB2-directed antibody-drug conjugates will likely drive prognosis in ERBB2-low disease, rather than intrinsic differences in biology between ERBB2-low and ERBB2-negative breast cancer. Here, ERBB2 is linked to breast cancer.